Synlogic (NASDAQ:SYBX) Stock Passes Below Fifty Day Moving Average – Here’s Why

Shares of Synlogic, Inc. (NASDAQ:SYBX) crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $1.24 and traded as low as $1.02. Synlogic shares last traded at $1.06, with a volume of 10,062 shares traded.

Synlogic Trading Up 0.0 %

The stock has a 50-day simple moving average of $1.24 and a 200 day simple moving average of $1.35. The company has a market cap of $12.40 million, a price-to-earnings ratio of -0.25 and a beta of 0.69.

Synlogic (NASDAQ:SYBX) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.04. As a group, research analysts forecast that Synlogic, Inc. will post -2.71 EPS for the current fiscal year.

About Synlogic

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.